INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CULVER CITY, Calif. --(BUSINESS WIRE)--Jul. 31, 2015-- NantKwest, Inc. (formerly Conkwest, Inc. ) (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell Therapy in First 35 Patients
5 out of 35 Durable Complete Responses Observed in Patients with Relapsed Third-Line Advanced Solid Tumors with Duration Ranging 4 to 24 Months CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 4, 2019-- Patrick Soon-Shiong , MD, Chairman and CEO of NantKwest (Nasdaq:NK), a leading clinical-stage,
View HTML
Toggle Summary NantKwest Announces Durable Complete Responses in Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological Malignancies
42% Of Patents Exhibited A Response, With Two Complete Responses In A Phase 1 Study Of 12 Patients With A Patient In Complete Remission 10 Years After Failing Transplant Therapy For Hodgkin’s Lymphoma, And A Second Patient In Complete Remission 2 Years After Failing Transplant Therapy In Multiply
View HTML
Toggle Summary NantKwest Announces Enhanced High-Affinity Activated Natural Killer (haNK) Cell Therapy in Preclinical Studies of HER2 Positive Breast Cancer at Presentation at the San Antonio Breast Cancer Symposium
CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 12, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest Announces FDA Grant of Orphan Drug Designation for the Company’s aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma
CULVER CITY, Calif. --(BUSINESS WIRE)--Mar. 20, 2017-- NantKwest, Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest Announces Landmark Study Published on high affinity haNK Cell Therapy in the Journal Oncotarget
Next Generation NK Cell Therapy Poised to Transition into Human Clinical Trials CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 22, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using
View HTML
Toggle Summary NantKwest Announces Launch of Initial Public Offering
CULVER CITY, Calif.--( BUSINESS WIRE )--NantKwest, Inc. (formerly known as Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the Natural Killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases, today
View HTML
Toggle Summary NantKwest Announces Launch of Merkel Cell Carcinoma Phase II Trial Deploying Novel Triple Combination of off-the-Shelf Natural Killer haNKⓇ Cell Therapy with Superagonist IL-15 Cytokine Therapy and PD-L1 Checkpoint Inhibitor Therapy
Study Tests Elimination Of Chemotherapy And Expands Upon Previous Combination Study Of NK Cell Therapy With N-803 Showing Promising Clinically Meaningful Responses In Merkel Cell Carcinoma Patients CULVER CITY, Calif. --(BUSINESS WIRE)--Jan. 9, 2019-- NantKwest Inc .
View HTML
Toggle Summary NantKwest Announces Multiple Presentations at the 2018 Society for Immunotherapy of Cancer Conference
Update on Off-The-Shelf CD16 Targeted NK Cell (haNK) and NANT Cancer Vaccine Program Including Interim Data Analysis for Pancreatic Cancer, Triple Negative Breast Cancer & Head and Neck Cancer Trials CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 5, 2018-- NantKwest (NASDAQ: NK), a leading,
View HTML
Toggle Summary NantKwest Announces New haNK Natural Killer Cell Patent Issuance Further Expanding Intellectual Property Estate
New haNK and T-haNK Based Natural Killer Cell Therapy Programs to Transition to Human Clinical Trials in 2019 CULVER CITY, Calif. --(BUSINESS WIRE)--Apr. 1, 2019-- NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the Company has
View HTML